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Congenital hypomyelinating disorders are a heterogeneous group of inherited leukoencephalopathies characterized by abnormal
myelin formation. We have recently reported a hypomyelinating syndrome characterized by diffuse cerebral hypomyelination with
cerebellar atrophy and hypoplasia of the corpus callosum (HCAHC). We performed whole-exome sequencing of three unrelated individ-
uals with HCAHC and identified compound heterozygous mutations in POLR3B in two individuals. The mutations include a nonsense
mutation, a splice-site mutation, and two missense mutations at evolutionally conserved amino acids. Using reverse transcription-PCR
and sequencing, we demonstrated that the splice-site mutation caused deletion of exon 18 from POLR3BmRNA and that the transcript
harboring the nonsense mutation underwent nonsense-mediated mRNA decay. We also identified compound heterozygous missense
mutations in POLR3A in the remaining individual. POLR3A and POLR3B encode the largest and second largest subunits of RNA
Polymerase III (Pol III), RPC1 and RPC2, respectively. RPC1 and RPC2 together form the active center of the polymerase and contribute
to the catalytic activity of the polymerase. Pol III is involved in the transcription of small noncoding RNAs, such as 5S ribosomal RNA
and all transfer RNAs (tRNA). We hypothesize that perturbation of Pol III target transcription, especially of tRNAs, could be a common
pathological mechanism underlying POLR3A and POLR3B mutations.Congenital hypomyelinating disorders form a heteroge-
neous group of central nervous system leukoencephalo-
pathies that is characterized by abnormal myelin forma-
tion. Although these conditions are readily recognized
by brain magnetic resonance imaging (MRI), many cases
are not diagnosed correctly.1 Several syndromes affecting
myelination, such as hypomyelination with hypodontia
and hypogonadotropic hypogonadism (4H) syndrome
(MIM 612440) and hypomyelination with atrophy of
the basal ganglia and cerebellum (H-ABC) (MIM
612438), have been described.2–5 We have recently
reported a hypomyelinating syndrome characterized by
diffuse cerebral hypomyelination with cerebellar atrophy
and hypoplasia of the corpus callosum (HCAHC).6
Individuals with HCAHC do not show hypodontia or
atrophy of the basal ganglia, which are observed in 4H
syndrome and H-ABC; however, diffuse hypomyelina-
tion, atrophy, or hypoplasia of the cerebellum and corpus
callosum are overlapping features of these three
syndromes, suggesting that there might be a common
underlying pathological mechanism.
Here, we report on four individuals with HCAHC
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644 The American Journal of Human Genetics 89, 644–651, Novembinformation and peripheral blood or saliva samples were
obtained from the family members after obtaining written
informed consent. Experimental protocols were approved
by the Institutional Review Board of Yokohama City
University. To identify pathogenic mutations, we per-
formed whole-exome sequencing of three probands from
three unrelated families (individuals 1, 3, and 4). DNAs
were captured with the SureSelect Human All Exon 50Mb
Kit (Agilent Technologies, Santa Clara, CA) and sequenced
with one lane per sample on an Illumina GAIIx (Illumina,
San Diego, CA) with 108 bp paired-end reads. Image
analysis and base calling were performed by sequence
control software real-time analysis and CASAVA software
v1.7 (Illumina). A total of 90,014,368 (individual 1),
86,942,264 (individual 3), and 92,168,758 (individual 4)
paired-end reads were obtained and aligned to the human
reference genome sequence (GRCh37/hg19) with MAQ7
and NextGENe software v2.00 with sequence condensa-
tion by consolidation (SoftGenetics, State College, PA).
This approach resulted in more than 88% of target exomes
being covered by ten reads or more (see Table S1, available
online). Single nucleotide variants (SNVs) were called with
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Figure 1. Mutations in POLR3B and POLR3A
(A) Pedigrees of four kindreds with HCAHC are shown.We identified fourmutations in POLR3B encoding RPC2 in three individuals from
two unrelated families and two mutations in POLR3A encoding RPC1 in one family. The segregation of each mutation is shown.
(B) Schematic representation of RPC2 (upper) and RPC1 (lower) proteins with Pfam domains (from Ensembl). Locations of each amino-
acid-altering mutation are depicted with electropherograms. All of the missense mutations occurred at evolutionally conserved amino
acids. Homologous sequences were aligned with the CLUSTALW website.
(C–F) 3D representations of RPC1 and RPC2 mutations. Mutated amino acids in RPC1 and RPC2 are shown along with their equivalent
positions in the homologous RPB1 and RPB2 subunits of RNA Polymerase II (amino acid and its position in parenthesis). The structure
and positions of mutations are illustrated by PyMOL with the crystal structure (PDB accession number 3GTP). RPB3, RPB9, and RPB11
subunits, which are specific to RNA Polymerase II, have been omitted from the figure. RPB1 is shown in green, RPB2 in sky blue, RPB5 in
yellow, RPB6 in dark blue, RPB8 in pink, RPB10 in orange, RPB12 in purple, DNA in brown, and RNA in red. Amino acids that interact
with mutated amino acids are also shown.
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Table 1. Clinical Features of the Individuals
Clinical Features Individual 1 Individual 2 Individual 3 Individual 4
Genes POLR3B POLR3B POLR3B POLR3A
Mutations, DNA c.1857-2A>C, c.2303G>A c.1857-2A>C, c.2303G>A c.1648C>T, c.2778C>G c.2690T>A, c.3013C>T
Mutations, protein p.Asn620_Lys652del,
p.Arg768His
p.Asn620_Lys652del,
p.Arg768His
p.Arg550X,
p.Asp926Glu
p.Ile897Asn,
p.Arg1005Cys
Gender M F F M
Current age (years) 27 30 16 17
Intellectual disability mild mild moderate mild
Cognitive regression – – – –
Seizures – – – –
Initial motor development normal normal normal normal
Age of onset (years) 3 3 2 4
Motor deterioration – – – þ
Wheelchair use – – – þ
Optic atrophy – – – –
Myopia þ þ – þ
Nystagmus þ þ – –
Abnormal pursuit þ þ þ –
Vertical gaze limitation þ þ þ –
Dysphagia – – þ –
Hypersalivation – – – –
Cerebellar signs þ þ þ þ
Tremor – þ þ þ
Babinski refex – – – –
Spasticity – – mild –
Peripheral nerve involvement – – – –
Nerve biopsy NA NA NA NA
Hypodontia – – – –
Hypogonadism þ þ – –
NA is an abbreviation for not available.detected with NextGENe. Called SNVs were annotated
with SeattleSeq Annotation.
We adopted a prioritization scheme to identify the
pathogenic mutation in each individual, similar to the
approach taken by recent studies (Table S2).8–10 First, we
excluded the variants registered in the dbSNP131 or 1000
Genome Project from all the detected variants. Then,
SNVs commonly detected by MAQ and NextGENe
analyses were selected as highly confident variants; 364
to 374 SNVs of nonsynonymous (NS) or canonical splice-
site (SP) changes, along with 113 to 124 small insertions
or deletions (indels), were identified per individual. We
also excluded variants found in our 55 in-house exomes,
which are derived from 12 healthy individuals and 43
individuals with unrelated diseases, reducing the number646 The American Journal of Human Genetics 89, 644–651, Novembof candidate variants to ~250 per individual. Assuming
that HCAHC is an autosomal-recessive disorder based on
two affected individuals in one pedigree (individuals 1
and 2), we focused on rare heterozygous variants that are
not registered in the dbSNP or in our in-house 55 exomes.
We surveyed all genes in each individual for two or more
NS, SP, or indel variants. We found three to eight candidate
genes per individual (Table S2). Among them, only
POLR3B encoding RPC2, the second largest subunit of
RNA Polymerase III (Pol III), was common in two individ-
uals (individuals 1 and 3). The inheritance of the variants
in POLR3B (transcript variant 1, NM_018082.5) was exam-
ined by Sanger sequencing. In individual 1, we confirmed
that a canonical splice-site mutation (c.1857-2A>C
[p.Asn620_Lys652del]), 2 bp upstream of exon 18, waser 11, 2011
Figure 2. Effects of Splice-Site and Nonsense Mutations in
POLR3B
(A) Schematic representation of the genomic structure of POLR3B
from exon 16 to 19. Exons, introns, and primers are shown by
boxes, dashed lines, and arrows, respectively. The mutation in
intron 17 is depicted as a red dot.
(B) RT-PCR analysis of individuals 1 and 2 with c.1857-2A>C and
a normal control. Two PCR products were detected from the indi-
vidual’s cDNA: the upper band is the wild-type (WT) transcript,
and the lower band is the mutant. Only a single wild-type ampli-
con was detected in the control.
(C) Sequence of WT and mutant amplicons clearly showed exon
18 skipping in the mutant allele.
(D) Analysis of the c.1648C>T mutation. Sequence of PCR prod-
ucts amplified with genomic (upper), cDNA from untreated cells
(middle), and cDNA from CHX treated cells (lower) as a template.
Although untreated cells show extremely low levels of c.1648C>T
mutant allele expression, cells treated to inhibit NMD show signif-
icantly increased levels of mutant allele expression.inherited from his father, and that a missense mutation
(c.2303G>A [p.Arg768His]) in exon 21 were inherited
from his mother (Figure 1A). The two mutations were
also present in an affected elder sister (individual 2) but
not present in a healthy elder brother. In individual 3,
we confirmed that a nonsense mutation (c.1648C>T
[p.Arg550X]) in exon 16 was inherited from her father
and that a missense mutation (c.2778C>G [p.Asp926Glu])
in exon 24 was inherited from her mother (Figure 1A). The
two mutations were not present in a healthy younger
brother. To examine the mutational effects of c.1857-
2A>C and c.1648C>T, reverse transcription PCR and
sequencing with total RNA extracted from lymphoblastoid
cells derived from the individuals was performed as
previously described.11 We demonstrated that the c.1857-
2A>C mutation caused deletion of exon 18 from the
POLR3B mRNA (Figures 2A–2C), resulting in an in-frame
33 amino acid deletion (p.Asn620_Lys652del) from RPC2
(Figure 1B). In addition, the mutated transcript harboring
the nonsense mutation (c.1648C>T) was found to be
expressed at a much lower level compared with the wild-
type transcript (Figure 2D). The expression level of the
mutated transcript was increased after treatment with
30 mM cycloheximide (CHX),11 which inhibits nonsense-
mediated mRNA decay (NMD), indicating that the mutant
transcript underwent NMD (Figure 2D). The two missense
mutations (p.Arg768His and p.Asp926Glu) found in the
three individuals occurred at evolutionary conserved
amino acids (Figure 1B). Among the other candidate genes
in individuals 1 and 3, MSLN (MIM 601051), encoding
mesothelin isoform 1 preproprotein that is cleaved into
megakaryocyte potentiating factor and mesothelin, is
a potential candidate in the family of individual 1 as its
homozygous variant segregated with the phenotype;
however, it is expressed in epithelial mesotheliomas,
and the mutation affects less conserved amino acid
(Table S3). The other candidate genes’ variants did not
cosegregate with the phenotype. Thus, mutations in
POLR3B are most likely to cause HCAHC in two families.
In individual 4, in whom no POLR3B mutations were
found, there were six candidate genes for an autosomal-
recessive model. Among them, POLR3A (MIM 614258,
GenBank accession number NM_007055.3), harboring
two missense mutations, appeared to be a primary candi-
date because it encodes the largest subunit of Pol III
(RPC1) (Figure 1A and Table S2). By Sanger sequencing,
we confirmed that a missense mutation (c.2690T>A
[p.Ile897Asn]) in exon 20 was inherited from his father
and that another missense mutation (c.3013C>T
[p.Arg1005Cys]) in exon 23 was inherited from his mother
(Figure 1A). The two mutations were not present in
a healthy younger sister. The two missense mutations
(p.Ile897Asn and p.Arg1005Cys) occurred at relatively
conserved amino acids (Figure 1B). In total, we found
four mutations in POLR3B and two mutations in POLR3A.
Evaluation of the missense mutations by PolyPhen-2
program showed that three mutations (p.Arg768His,The Americanp.Asp926Glu, and p.Ile897Asn) were probably damaging
and that p.Arg1005Cys is tolerable. The c.2303G>A muta-
tion (POLR3B) was found in one allele out of 540 Japanese
control chromosomes. The remaining five mutations were
not detected in 540 Japanese control chromosomes, indi-
cating that the mutations are very rare in the Japanese
population. Among the other candidate genes in individ-
uals 4, IGSF10, a member of immunoglobulin superfamily,
is a potential candidate because its variants segregated with
the phenotype (Table S3); however, considering a close
relationship between POLR3A and POLR3B, and the fact
that POLR3A mutations have been recently reported in
hypomyelinating leukodystrophy (see below),12 POLR3A
abnormality is the most plausible culprit for HCAHC in
individual 4.
The structure of Pol III13,14 and Pol II15,16 is highly
homologous, especially in the largest subunits. Thus, we
extrapolated the mutations of RPC1 or RPC2 onto the
structure of yeast Pol II (Protein Data Bank [PDB] accession
number 3GTP)17 (Figure 1C). RPB1 and RPB2 subunits ofJournal of Human Genetics 89, 644–651, November 11, 2011 647
Figure 3. Brain MRI of Individuals with POLR3B and POLR3A
Mutations
(A, C, E, and G) T2-weighted axial images through the basal
ganglia. High-intensity areas in the white matter were observed
in all individuals.
(B, D, F, and H) T1-weighted midline sagittal images. All the
individuals showed hypoplastic corpus callosum (arrowheads)
and atrophy of cerebellum (arrows).yeast Pol II are homologous to RPC1 and RPC2 of Pol III,
respectively. Asn620_Lys652 in RPC2 corresponds to
Tyr679_Lys712 in RPB2. The deletion of Asn620_Lys652
(Tyr679_Lys712) would destroy a structural core of RPB2,
leading to loss of RPB2 function. In addition, Arg768
(Arg852 in RPB2) interacts with the main-chain carbonyl
group of Arg70 of the RPB12 subunit, and Asp926
(Asp1009 in RPB2) interacts with the side chain of Arg48
of the RPB10 subunit of Pol II (Figure 1D). Arg768His
(Arg852His) and Asp926Glu (Asp1009Glu) substitutions
are considered to disturb these subunit interactions,
leading to dysfunction of the polymerase. Therefore, struc-
tural prediction suggests that the mutations in POLR3B
(RPC2) could affect Pol III function. On the other hand,
Ile897 and Arg1005 in RPC1 correspond to Val863 and
Arg1036 in RPB1, respectively. Ile897 (Val863) has hydro-
phobic interactions with Leu170 and Pro176 of the RPB5
subunit and with Phe900 (Phe866) of the RPB1 subunit
of Pol II (Figure 1E). Ile897Asn (Val863Asn) substitution
is likely to disturb this interaction. Arg1005 (Arg1036)
stabilizes interaction between RPB1 and RPB8 subunits
(Figure 1F). The Arg1005Cys (Arg1036Cys) substitution
appears to make this interaction unstable. Thus mutations
in POLR3A are also predicted to affect Pol III function.
Clinical features of individuals with POLR3A or POLR3B
mutations are presented in Table 1. MRI revealed high-
intensity areas in the white matter in T2-weighted images,
cerebellar atrophy, and a hypoplastic corpus callosum in all
four individuals (Figure 3). Individuals 1 and 2 showed an
extremely similar clinical course. They developed normally
during their early infancy, i.e., walking unaided at 15 and
14 months, and uttering a few words at 12 and 13 months,
respectively. After the age of 3, individual 1 presented with
unstable walking and frequent stumbling and falling
down, and individual 2 became poor at exercise. They
both had severe myopia (corrected visual acuity of 0.7
and 0.5 at most, respectively). They graduated from
elementary, junior high, and high schools with poor
records, and the intelligence quotient (IQ) of individual 2
was 52 (WAIS-III). In individual 1, unstable walking was
prominent at around 18 years, and he could not ride
a bicycle because of ataxia; however, he could drive an
automobile. Amenorrhea was noted in individual 2, and
was successfully treated by hormone therapy. Individual
1 showed several signs of hypogonadism, including
absence of underarm and mustache hair, thin pubic hair
(Tanner II), and serum levels of testosterone, follicle stimu-
lating hormone, and luteinizing hormone that were below
normal for age 27. Neurological examination of both
individuals revealed mild horizontal nystagmus, slowing
of smooth-pursuit eye movement, and gaze limitation,
especially in vertical gazing, hypotonia, mildly exagger-
ated deep-tendon reflex (patellar and Achilles tendon
reflex) with negative Babinski reflex, and cerebellar signs
and symptoms, including ataxic speech, wide-based ataxic
gait, dysdiadochokinesis, and dysmetria. Clinical informa-
tion for individual 3 has been reported previously.6 Addi-648 The American Journal of Human Genetics 89, 644–651, Novembtional findings are as follows: slowing of smooth-pursuit
eye movement, gaze limitation in vertical gazing, normal
auditory brain responses (ABR), cerebral symptoms with
mild spasticity, and intellectual disability (an IQ of 43
according to the WISC-III test), and no myopia but hyper-
metropic astigmatism. She showed no deterioration
besides a mild dysphagia and walks herself to a school for
the disabled. Individual 4 developed normally during hiser 11, 2011
early infancy, had normal head control at 3 months, was
speaking a few words at 12 months, and was walking un-
aided at 14 months. His parents noted mild tremors
around 4 years. He had normal stature, weight, and head
circumference. Although he had severe myopia, his eye
movement was smooth with no limitation or nystagmus.
He had sensory neuronal deafness on the left side. He
showed normal muscle tone and had no spasticity or
rigidity. His tendon reflexes were slightly elevated with
a negative Babinski reflex. Cerebellar signs were noted;
expressive ataxic explosive speech, intension tremor,
poor finger to nose test, dysdiadochokinesis, dysmetria,
and wide-based ataxic gait. His intelligence quotient was
57 (according to the WISC-III test). His peripheral nerve
conduction velocity was within the normal range and his
ABR showed normal responses on the right side. He
suffered motor deterioration around age 14 and became
wheelchair bound.
In this study, we successfully identified compound
heterozygous mutations in POLR3A and POLR3B in indi-
viduals with HCAHC. Very recently, Bernard et al.12 re-
ported that POLR3A mutations cause three overlapping
leukodystrophies, including 4H syndrome, suggesting
that HCAHC is, at least in part, within a wide clinical spec-
trum caused by POLR3A mutations. The p.Arg1005Cys
mutation was shared between individual 9 in their report
and our individual 4. All 19 individuals with POLR3A
mutations showed progressive upper motor neuron
dysfunction and cognitive regression. In addition, indi-
vidual 9 showed abnormal eye movement, hypodontia,
and hypogonadism. None of these features were recog-
nized in our individual 4; these differences further support
phenotypic variability of POLR3A mutations.12 Given the
phenotypic similarities among 4H syndrome, HCAHC,
and H-ABC, there is a possibility that H-ABC is also allelic
and caused by recessive mutations in either POLR3A or
POLR3B.
Pol III consists of 17 subunits and is involved in the
transcription of small noncoding RNAs, such as 5S ribo-
somal RNA (rRNA), U6 small nuclear RNA (snRNA), 7SL
RNA, RNase P, RNase MRP, short interspersed nuclear
elements (SINEs), and all transfer RNAs (tRNAs). Pol III-
transcribed genes are classified into three types based on
promoter elements and transcription factors. 5S rRNA is
a solo type I gene. Type II genes include tRNA, 7SL
RNA, and SINEs. Type III genes include U6 snRNA, RNase
P, and RNase MRP.18–20 The Pol III system is important for
cell growth in yeast, and its transcription is tightly regu-
lated during the cell cycle.20 In zebrafish, polr3b mutant
larvae that have a deletion of 41 conserved amino acids
(D239-279) from the Rpc2 protein showed a proliferation
deficit in multiple tissues, including intestine, endocrine
pancreas, liver, retina and terminal branchial arches.21
In the mutants, the expression levels of tRNA were signif-
icantly reduced, whereas the level of 5S rRNA expression
was not changed, suggesting that this polr3b mutation
can differentially affect Pol III target promoters.21 RPC2The Americancontributes to the catalytic activity of the polymerase
and forms the active center of the polymerase together
with the largest subunit, RPC1.22 Thus, it is reasonable
to consider that mutations in POLR3A and POLR3B cause
overlapping phenotypes. Indeed, three individuals with
POLR3B mutations showed diffuse cerebral hypomyelina-
tion, atrophy of the cerebellum and corpus callosum, and
abnormal eye movements that overlap with POLR3A
abnormalities.12 Furthermore, two out of three individ-
uals showed hypogonadism, suggesting a common patho-
logical mechanism between POLR3A and POLR3B muta-
tions. In the zebrafish polr3b mutants there were no
defects of the central nervous system other than a reduced
size of the retina, probably reflecting species differences;
however, the reduced level of tRNA in the polr3b mutants
raises the possibility that defects of tRNA transcription by
Pol III could be a common pathological mechanism
underlying POLR3A and POLR3B mutations. Supporting
this idea, mutations in two genes involved in aminoacyla-
tion activity of tRNA synthetase cause defects of myelina-
tion in central nervous system: DARS2 (MIM 610956) and
AIMP (MIM 603605).23,24 In addition, mutations in four
genes encoding aminoacyl-tRNA synthetase cause Char-
cot-Marie-Tooth disease (MIM 613641, 613287, 601472,
and 608323), resulting from demyelination of peripheral
nerve axons: KARS (MIM 601421), GARS (MIM 600287),
YARS (MIM 603623), and AARS (MIM 601065).25–28
Thus, it is very likely that regulation of tRNA expression
is essential for development and maintenance of myelina-
tion in both central and peripheral nervous systems.
An interesting clinical feature of POLR3B mutations is
the absence of motor deterioration. All three individuals
with POLR3B mutations could walk without support at
ages 16, 27, and 30, whereas individual 3 with POLR3A
mutations hadmotor deterioration around age 14. Bernard
et al.12 also reported progressive upper motor neuron
dysfunction and cognitive regression in individuals with
POLR3Amutations. Thus, there is a possibility that pheno-
types caused by POLR3A mutations could be more severe
and progressive than POLR3B mutant phenotypes. Identi-
fication of a greater number of cases with POLR3B muta-
tions is required to confirm this hypothesis.
In conclusion, our data, together with that of a previous
report,12 demonstrate that mutations in Pol III subunits
cause overlapping autosomal-recessive hypomyelinating
disorders. Establishment of an animal model will facilitate
our understanding of the pathophysiology of the multiple
defects caused by Pol III mutations.
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